Antibiotic lock: In vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37°C

Hemodialysis International

Volumn 13, Issue 3, 2009, Pages 322-328

  Battistella, Marisa ^a,b,d   Walker, Scott ^b,c   Law, Shirley ^c   Lok, Charmaine ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d NONE   (Canada)

Author keywords

Catheters; Citrate; Dialysis; Lock; Vancomycin

Indexed keywords

CITRATE SODIUM; POLYVINYLCHLORIDE; VANCOMYCIN;

ARTICLE; DIALYSIS CATHETER; DRUG DEGRADATION; DRUG STABILITY; DRUG STORAGE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; REPRODUCIBILITY; ROOM TEMPERATURE; VASCULAR ACCESS DEVICE;

ANTI-BACTERIAL AGENTS; ARTERIOVENOUS SHUNT, SURGICAL; BACTEREMIA; CATHETERIZATION; CATHETERS, INDWELLING; CHROMATOGRAPHY, LIQUID; CITRATES; DRUG STABILITY; HUMANS; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; VANCOMYCIN;

EID: 69249192964     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00368.x     Document Type: Article

References (41)

1. Mendelssohn DC, Ethier J, Elder SJ, Saran R, Port FK, Pisoni RL. Haemodialysis vascular access problems in Canada: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). Nephrol Dial Transplant. 2006; 21:721-728.
2. Lee T, Barker J, Allon M. Tunneled catheters in hemodialysis patients: Reasons and subsequent outcomes. Am J Kidney Dis. 2005; 46:501-508.
3. U.S. Renal Data System. USRDS 2008 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Betheseda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
4. Oliver MJ, Lok CE, Shi J, Rothwell D. Dialysis therapy for persons with diabetes. In: Hux JE, Booth GL, Slaughter PM, Laupacis A, eds. Diabetes In Ontario: An ICES Practice Atlas: Institute For Clinical Evaluative Sciences. Insitute for Clinical Evaluative Sciences. Toronto, ON, Canada; 2002: 165-168.
5. Jindal K, Chan CT, Deziel C, et al. Chapter 4: Vascular access. J Am Soc Nephrol. 2006; 17(Suppl 1):S16-S23.
6. Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006; 48:S176-S247.
7. Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: Initial results. Am J Infect Control. 2002; 30:288-295.
8. Schaubel DE, Fenton SSA. Trends in mortlaity rates on hemodialysis in Canada, 1981-1997. Kidney Int. 2000; 57:S66-S73.
9. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000; 58:1758-1764.
10. Saxena AK, Panhorota BR, Al-Mulhim AS. Vascular access related infections in hemodialysis patients. Saudi J Kidney Dis Transplant. 2005; 16:46-71.
11. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001; 60:1443-1451.
12. Beathard GA, Posen GA. Initial clinical results with the lifesite hemodialysis access system. Kidney Int. 2000; 58:2221-2227.
13. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int. 2004; 66:801-805.
14. Weijmer MC, van den Dorpel MA, Van de Ven PJ. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005; 16:2769-2777.
15. Dogra GK, Herson H, Hutchison B. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: A randomized controlled study. J Am Soc Nephrol. 2002; 13:2133-2139.
16. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant. 2004; 19:1546-1551.
17. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for disease control and prevention. Morb Mortal Wkly Rep Recomm Rep. 2002; 9:1-29.
18. Marr KA, Sexton SD, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med. 1997; 127:275-280.
19. Shaffer D. Catheter-related sepsis complicating long-term, tunnelled central venous dialysis catheters: Management by guidewire exchange. Am J Kidney Dis. 1995; 25:593-596.
20. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis. 1999; 34:1114-1124.
21. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol. 1999; 10:1045-1049.
22. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: A new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. J Parenter Enteral Nutr. 1988; 12:185-189.
23. Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. 2002; 61:1136-1142.
24. Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant. 1993; 8:231-234.
25. Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: Effect of bacterial pathogen. Nephrol Dial Transplant. 2004; 19:1237-1244.
26. Vardhan A, Davies J, Daryanani I, Crowe A, McClelland P. Treatment of haemodialysis catheter-related infections. Nephrol Dial Transplant. 2002; 17:1149-1150.
27. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters-an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2006; 22:471-476.
28. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM. Trisodium citrate 4% - an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant. 2006; 22:477-483.
29. Wentworth DW, Kim FJ, Lentino JR, et al. Citrate may be the anticoagulant of choice to prevent clotting of antibiotic locks used in vascular access devices. J Am Soc Nephrol. 1999; 10:222A.
30. Wazny L, Walker S, Moist L. Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions. Am J Health Syst Pharm. 2005; 62:1548-1550.
31. Lu PL, Tsai JC, Chiu YW, et al. Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and tehir family members. Nephrol Dialy Transplant. 2008; 23:1659-1665.
32. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991; 16:249-255.
33. Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm. 1983; 40:1159-1160.
34. Trissel LA, Flora KP. Stability studies: Five years later. Am J Hosp Pharm. 1988; 45:1569-1571.
35. Anon, Tremblay SJ, Walker SE, Murdoch L, O'Brodovich M. Policy for publication of chemical stability study manuscripts. Can J Hosp Pharm. 1990; 43:3-4.
36. Walker SE, Birkhans B. Stability of intravenous vancomycin. Can J Hosp Pharm. 1988; 41:233-238.
37. Freiman JA, Chalmers TC, Smith H Jr., Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978; 299:690-694.
38. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther. 1986; 39:489-490.
39. Manley HJ, Huke MA, Dyksstra MA, Bedenbaugh AV. Antibiotic prescribing evaluation in an outpatient hemodialysis clinic. J Pharm Technol. 2002; 18:128-132.
40. Vercaigne LM, Sitar DS, Penner SB, Bernstein K, Wang GQ, Burczynski FJ. Antibiotic-heparin lock: In vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy. 2000; 20:394-399.
41. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for disease control and prevention. Morb Mortal Wkly Rep Recom Rep. 2002; 51(RR-10):1-29.